Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity
NARFI
1 other identifier
interventional
109
1 country
1
Brief Summary
Liver stiffness measurement (LSM) by non invasive methods is increasingly used to estimate liver fibrosis in patients with chronic liver diseases. However, there is growing evidence that fibrosis is not the only determinant of liver stiffness. Indeed inflammation, cholestasis, congestion could also interfere with stiffness measurements. Acoustic radiation force impulse imaging (ARFI) is a new technology to perform real time LSM. Using a standard ultrasonographic probe, it offers elastography with a flexible metering box at variable depth, allowing the examination of specific area.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2010
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 5, 2010
CompletedFirst Posted
Study publicly available on registry
March 8, 2010
CompletedStudy Start
First participant enrolled
April 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2013
CompletedNovember 7, 2014
November 1, 2014
3 years
March 5, 2010
November 6, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The elasticity parameter will be for each patient the median of ten ARFI values (m/s) in the right liver.
One or two 30 min visit according to the patient group
Secondary Outcomes (2)
Inter and intra observer reproducibility
Three 30 min visits in healthy volunteer group.
Median (m/s) of ARFI values between before and after effective treatment for liver reversible disease
From patient admission until patient healing in groups F&G.
Study Arms (7)
Group A
OTHERhealthy volunteers
Group B
OTHERpatients with supposed disease free liver (normal hepatic and pancreatic biochemistry)
Group D
OTHERpatients with cirrhosis
Group E
OTHERpatients with liver tumour and surgery indication
Group F
OTHERpatients with reversible liver diseases and with acute left cardiac insufficiency
Group C
OTHERpatients with non cirrhotic hepatopathy
Group G
OTHERpatients with reversible liver diseases and with biliary cholestasis
Interventions
ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a "light" apnea. For group A the measurement is made by a second and a third investigator during the same examination.
Eligibility Criteria
You may qualify if:
- Man or Woman
- Age\> 18 years old
- Able to understand the study and to give informed consent
- Informed consent signed by patient and investigator before any study required examination
- With a valid health insurance
- Group A : healthy volunteers without known liver disease
- Group B : voluntary patients without known liver disease
- Group C and D Patient with a diagnosed chronic liver disease
- Group E : patients with liver tumors (benign or malignant) with surgical indication
- Group F : patients with acute right heart insufficiency diagnosed by a cardiologist
- Group G :patients with biliary cholestasis and imaging evidence of biliary dilatation
You may not qualify if:
- Patient under 18 years old
- Not able to understand the study or to give their consent.
- Pregnant woman
- Severe respiratory insufficiency
- Unable to perform a "light" apnea .
- hemodynamic instability (cardiogenic shock, septic or anaphylactic) possibility of disruption of the elasticity and inability to carry patient.
- Chronic heart insufficiency.
- deprived of their liberty by court
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Bordeaux
Bordeaux, 33075, France
Related Publications (5)
Bonekamp S, Kamel I, Solga S, Clark J. Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J Hepatol. 2009 Jan;50(1):17-35. doi: 10.1016/j.jhep.2008.10.016. Epub 2008 Nov 8.
PMID: 19022517BACKGROUNDCastera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008 May;48(5):835-47. doi: 10.1016/j.jhep.2008.02.008. Epub 2008 Feb 26.
PMID: 18334275BACKGROUNDFriedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008 Apr;134(4):960-74. doi: 10.1053/j.gastro.2008.01.034. Epub 2008 Jan 18.
PMID: 18395077BACKGROUNDFerraioli G, Gulizia R, Filice C. Real-time elastography in the assessment of liver fibrosis. AJR Am J Roentgenol. 2007 Sep;189(3):W170. doi: 10.2214/AJR.07.2318. No abstract available.
PMID: 17715090BACKGROUNDFriedrich-Rust M, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, Sarrazin C. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol. 2007 Mar;188(3):758-64. doi: 10.2214/AJR.06.0322.
PMID: 17312065BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nora FRULIO, Md MSc
University Hospital, Bordeaux
- STUDY CHAIR
Adelaïde Doussau, MD, Msc
University Hospital, Bordeaux
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 5, 2010
First Posted
March 8, 2010
Study Start
April 1, 2010
Primary Completion
April 1, 2013
Study Completion
April 1, 2013
Last Updated
November 7, 2014
Record last verified: 2014-11